1. Home
  2. ITRG vs PSNL Comparison

ITRG vs PSNL Comparison

Compare ITRG & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra Resources Corp.

ITRG

Integra Resources Corp.

HOLD

Current Price

$3.79

Market Cap

482.5M

ML Signal

HOLD

Logo Personalis Inc.

PSNL

Personalis Inc.

HOLD

Current Price

$7.90

Market Cap

746.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRG
PSNL
Founded
1997
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
482.5M
746.8M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
ITRG
PSNL
Price
$3.79
$7.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
$4.13
$10.71
AVG Volume (30 Days)
1.7M
1.4M
Earning Date
11-12-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.08
N/A
Revenue
$219,125,000.00
$69,103,000.00
Revenue This Year
$965.93
N/A
Revenue Next Year
$9.39
$20.33
P/E Ratio
$50.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.79
$2.83
52 Week High
$4.69
$11.40

Technical Indicators

Market Signals
Indicator
ITRG
PSNL
Relative Strength Index (RSI) 47.55 41.51
Support Level $3.98 $7.88
Resistance Level $4.52 $9.10
Average True Range (ATR) 0.25 0.47
MACD -0.08 -0.09
Stochastic Oscillator 13.50 12.87

Price Performance

Historical Comparison
ITRG
PSNL

About ITRG Integra Resources Corp.

Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.

About PSNL Personalis Inc.

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Share on Social Networks: